Every material Form 8-K 4D Molecular Therapeutics, Inc. has filed with the SEC since July 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
4D Molecular Therapeutics said first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema, and reported 2-year data from the SPECTRA trial. The SPECTRA results cover a small group of 9 patients at the Phase 3 dose, and the company describes the 75% treatment burden reduction as a retrospective estimate.
4SIGHT is a global Phase 3 trial with 514 treatment-naive DME patients, comparing 4D-150 against aflibercept 2 mg Q8W.
SPECTRA 2-year safety (N=22): no intraocular inflammation and no ocular serious adverse events reported.
At the Phase 3 dose (n=9), mean BCVA gain was +10.8 letters and mean CST reduction was -176 µm.
Reported supplemental injections were 61% lower than the 13.0 projected with on-label aflibercept; 2 of 9 (22%) patients remained injection-free.
4DMT reported a second-quarter 2026 net loss of $72.9 million, up from $54.7 million a year earlier, as research and development spending rose to $68.3 million from $48.0 million on its 4D-150 Phase 3 wet AMD trials. Collaboration revenue was $3.8 million, compared with an insignificant amount a year earlier. The company had $430.6 million in cash and marketable securities at June 30, 2026, and said this should fund operations into the second half of 2028, after securing a credit facility of up to $200 million from Hercules Capital with a $20 million initial draw.
Net loss was $72.9 million, or $1.04 per share, for the three months ended June 30, 2026, versus $54.7 million, or $0.98 per share, a year earlier.
R&D expenses were $68.3 million versus $48.0 million; G&A expenses were $12.5 million versus $11.5 million.
Cash, cash equivalents and marketable securities were $430.6 million at June 30, 2026, down from $514.0 million at December 31, 2025.
Hercules Capital credit facility of up to $200 million; initial draw of $20 million at closing.
4D Molecular Therapeutics reported two-year data from its PRISM Phase 2b trial of 4D-150 in a broad wet age-related macular degeneration population, with data cutoff May 18, 2026. The company said vision was consistently maintained, retinal thickness was consistently controlled, and treatment burden was reduced by 78% overall and 87% in the recently diagnosed subgroup, with no new inflammation cases after the first 28 weeks.
Overall cohort: 78% treatment burden reduction, 2.7 mean supplemental injections per patient vs. 12.0 projected with aflibercept 2 mg Q8W
Recently diagnosed subgroup (n=15 at 3E10 vg/eye): 87% reduction, 1.6 mean supplemental injections per patient
Safety: 2.8% (2 of 71) of patients had mild intraocular inflammation within the first 28 weeks; no new cases since
The 3E10 vg/eye dose was chosen for the 4FRONT Phase 3 trials
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every 4D Molecular Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →